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Background
Human immunodeficiency virus (HIV) infection has
posed a significant global threat to health care, more so in
developing countries. Peripheral nerve involvement has
been documented with distal sensory polyneuropathy
(DSP) as the commonest manifestation. The pattern and
risk factors for DSP have not been adequately defined in
this patient population especially in a low resource set-
ting. This study aims to determine the frequency of DSP,
and the effect of demographic and other clinical variables
on the clinical manifestation of DSP, among HIV positive
patients from South East Nigeria.
Methods
This is a case control study. The study took place at the
University of Nigeria Teaching Hospital Enugu. Two
cohorts of HIV positive patients (drug naïve and patients
on HAART) were recruited and studied with HIV negative
age and sex matched controls. Study participants were
classified as asymptomatic or symptomatic if they had
symptoms such as paraesthesias, numbness, and burning
sensation. Objective testing was done, and DSP diagnosed
if patient displayed abnormalities in 2 or more of the fol-
lowing: ankle reflex, vibration perception threshold using
the Bio-Thesiometer and pressure sensation with 10 g
monofilament.
Results
A total of 200 HIV positive study participants (100 drug
naïve and 100 patients on HAART) and 100 HIV negative
controls were recruited. The mean age of drug naïve
patients was 35.11 ± 8.71 years while that for patients on
HAART and controls were 35.15 ± 8.00 years and 35.58 ±
8.38 years respectively. There was no significant difference
in the mean age (p = 0.908). Eighty-five patients (42.5%)
had DSP. This was made up of 37 drug naïve patients and
48 patients on HAART. Age (p = 0.041), height (p = 0.002)
and low hemoglobin (p < 0.001) were found to be the risk
factors for DSP in the study participants. Though DSP
occurred more in patients on HAART, the difference was
not statistically significant. The duration on HAART may
have affected the result.
Conclusion
DSP is commoner in HIV infection. Low hemoglobin,
height and advancing age were significantly associated
with DSP while body mass index and CD4 count did not
affect DSP in this study. Though DSP occurred more in
patients on HAART, the difference was not statistically sig-
nificant. Vibration perception threshold had the highest
predictive accuracy for DSP in this study. There is need for
all HIV patients especially those with low hemoglobin,
tall stature and advancing age to be assessed for distal sen-
sory polyneuropathy.
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